Eli Lilly’s Taltz and Zepbound combo delivers superior results in landmark psoriatic arthritis trial

Eli Lilly and Company (NYSE:LLY) is one of the best future stocks to buy for the long term. On January 8, Eli Lilly announced ...
Morningstar

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis ...

At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to ≥10% weight reduction with concomitant Taltz and ...